Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Prolonged venetoclax (VEN) plus hypomethylating agent (HMA) therapy in non-promyelocytic AML: A single-centre retrospective cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

CCChen CaoXJXinwen Jiang

Discussion

Loading...

Member takes

Overview

Retrospective cohort study shows prognostic factors influencing survival in elderly patients with AML, suggesting strategies for risk stratification.

Key Points

  • Progression-free survival was notably influenced by factors like TP53 mutation and age ≥ 60 years.
  • In 88 patients analyzed, 34 relapsed while 22 died during follow-up, indicating significant survival challenges.
  • Cox proportional hazards regression revealed TP53 mutations lead to a 4.7 times higher risk of death compared to wild-type patients.
  • Findings highlight the importance of genetic factors in AML, supporting tailored treatment approaches based on risk stratification.

Cite This Study

Cao et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e5b4https://doi.org/10.1182/blood-2025-6905
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1IDH1 mutation predicts response and survival in treatment-naïve Acute Myeloid Leukemia patients receiving with venetoclax with a hypomethylating agent2025
  2. 2Contemporary outcomes of octa‐nonagenarians with newly diagnosed acute myeloid leukemia2025 · 4 citations
  3. 3Genetic risk model to predict outcomes for AML treated with HMA and venetoclax2025
  4. 4Venetoclax plus hypomethylating agent as first- and second-line treatment in patients with AML: A single-center experience2025
  5. 5Predictors of 90-day mortality in elderly and unfit AML patients treated with single-agent hypomethylating agents or in combination with venetoclax2025